Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Castration Resistant Prostate Cancer
45%
Malignant Neoplasm
30%
Androgen
30%
Docetaxel
28%
Clinical Trial
27%
Prostate Specific Antigen
27%
Overall Survival
22%
Neoplasm
21%
Disease
21%
Progression Free Survival
19%
Pharmacokinetics
17%
Renal Cell Carcinoma
16%
Chemotherapy
16%
Solid Malignant Neoplasm
16%
Placebo
13%
Phase II Trials
11%
Enzalutamide
9%
Sunitinib
9%
Kidney Metastasis
9%
Androgen Receptor
8%
Atrasentan
8%
Pharmacodynamics
7%
Disease Exacerbation
7%
Recurrent Disease
7%
Adverse Event
7%
Bone Metastasis
6%
Histone Deacetylase Inhibitor
6%
Biological Marker
6%
Abiraterone
6%
Cancer Growth
5%
Bevacizumab
5%
Arylbutyric Acid Derivative
5%
Medicine and Dentistry
Prostate Cancer
71%
Malignant Neoplasm
28%
Clinical Trial
19%
Castration Resistant Prostate Cancer
18%
Clear Cell Renal Cell Carcinoma
17%
Prostate Specific Antigen
15%
Overall Survival
14%
Androgen Deprivation Therapy
13%
Disease
13%
Progression Free Survival
12%
Neoplasm
11%
Metastatic Carcinoma
10%
Docetaxel
9%
Radiation Therapy
8%
Arm
8%
Sunitinib
8%
Androgen
7%
Nivolumab
7%
Prostatectomy
7%
Hazard Ratio
7%
Androgen Receptor
6%
Oncology
6%
Kidney Metastasis
6%
Cancer Cell
6%
Enzalutamide
6%
Phase II Trials
6%
Placebo
6%
Recurrent Disease
6%
Cancer Therapy
5%
Electrocorticography
5%
Abiraterone
5%
Histone Deacetylase Inhibitor
5%
Quality of Life
5%
Keyphrases
Prostate Cancer
37%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
22%
Docetaxel
21%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
17%
Prostate-specific Antigen
16%
Androgen Deprivation Therapy
16%
Phase II Trial
15%
Overall Survival
14%
Clinical Trials
13%
Castration-resistant Prostate Cancer
11%
Metastatic Renal Cell Carcinoma (mRCC)
9%
Hormone-sensitive Prostate Cancer
9%
Chemotherapy
9%
Renal Cell Carcinoma
8%
Phase II Study
8%
Atrasentan
8%
Progression-free Survival
8%
Recurrent Prostate Cancer
8%
Enzalutamide
7%
Placebo
7%
Hazard Ratio
7%
Nivolumab
6%
Phase I Study
6%
Confidence Interval
6%
Advanced Renal Cell Carcinoma
6%
In Cancer
5%
Advanced Prostate Cancer
5%
Disease Progression
5%
Bone Metastasis
5%
High Dose
5%
Pharmacokinetics
5%
Abiraterone
5%
Prostate Cancer Patients
5%
High Risk
5%
Nave
5%
Cancer Clinical Trials
5%
Radical Prostatectomy
5%
Sunitinib
5%
Solid Tumors
5%